icad inc.
iCAD, Inc. provides cancer detection and therapy solutions in the US through two segments: Detection and Therapy. The company offers ProFound AI for breast tomosynthesis and mammography, PowerLook density assessment, and ProFound Risk breast cancer risk analysis. Formerly known as Howtek, it changed its name to iCAD in 2002.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (3.45) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 3.5 |